Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

• Status: NOT_YET_RECRUITING
• Trial end date: 2025-12-01

Summary

This study is a Phase II, single-arm, open-label, non-randomized, dose-escalation clinical trial to evaluate the efficacy and safety of ssCART-19 Cell Injection in the treatment of patients with CD19 positive Relapsed or Refractory acute lymphoblastic leukemia, including central nervous system infiltration.

• Phase: PHASE2

Details

• Lead Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
• Collaborators: Peking University People's Hospital; The First Affiliated Hospital of Soochow University
• Treatments: Cyclophosphamide; fludarabine